AZD9793

AZD9793 is a T-cell engager developed by AstraZeneca. Its target is Glypican-3 (the sponsor names GPC3). The sponsor states: AZD9793 is a T-cell-engaging antibody that targets GPC3 on tumour cells, dosed intravenously and subcutaneously in the first-in-human RHEA-1 study, with a focus on hepatocellular carcinoma. ClinicalTrials.gov describes the intervention as: T cell-engaging antibody that targets GPC3 on tumour cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hepatocellular carcinoma. The largest, NCT06795022, plans to enrol 304 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.